Adtralza (tralokinumab-ldrm) price in pakistan

Adtralza (tralokinumab-ldrm) is a fully human IgG4 monoclonal antibody developed for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. By targeting and neutralizing interleukin-13 (IL-13), a key cytokine involved in the inflammatory process of atopic dermatitis, Adtralza helps reduce the symptoms associated with this chronic skin condition.

Mechanism of Action

Tralokinumab specifically binds to IL-13, inhibiting its interaction with the IL-13 receptors. By neutralizing IL-13, tralokinumab reduces the inflammatory responses and skin barrier dysfunction characteristic of atopic dermatitis.

Indications

Adtralza is indicated for the treatment of moderate-to-severe atopic dermatitis in:

• Adults and adolescents (12 years and older): whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adtralza can be used with or without topical corticosteroids.

Contraindications

Adtralza is contraindicated in patients who have known hypersensitivity to tralokinumab-ldrm or any excipients in the formulation. Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported.

Side Effects

Common side effects of Adtralza include:

• Upper respiratory tract infections: such as the common cold.
• Eye and eyelid inflammation: including redness, swelling, and itching.
• Injection site reactions: pain, redness, or swelling at the injection site.
• Eosinophilia: an increased number of eosinophils (a type of white blood cell).

Patients should be monitored for hypersensitivity reactions and advised to seek immediate medical attention if they experience symptoms such as chest tightness, difficulty breathing, or swelling of the face, lips, or throat.

Pricing in Different Countries

The cost of Adtralza varies across different countries. Below is a table summarizing the approximate monthly price in select countries:

Prices are approximate and may vary based on pharmacy, insurance coverage, and local regulations.

Availability and Pricing in Pakistan

As of now, specific pricing information for Adtralza in Pakistan is not readily available. Patients in Pakistan interested in Adtralza should consult with their healthcare providers or contact local pharmacies for information on availability and pricing. Additionally, international patient assistance programs may offer options to access medications not yet available locally.

Top Global Brands for Atopic Dermatitis Treatment

Several pharmaceutical companies have developed treatments for atopic dermatitis. Here are five notable brands:

1. Sanofi and Regeneron Pharmaceuticals: Manufacturers of Dupixent (dupilumab), a monoclonal antibody used to treat moderate-to-severe atopic dermatitis.
2. Pfizer: Producer of Cibinqo (abrocitinib), an oral Janus kinase (JAK) inhibitor indicated for moderate-to-severe atopic dermatitis.
3. AbbVie: Offers Rinvoq (upadacitinib), another JAK inhibitor approved for the treatment of moderate-to-severe atopic dermatitis.
4. Leo Pharma: Developer of Adtralza (tralokinumab-ldrm), the subject of this overview.
5. Eli Lilly and Company: Provides Olumiant (baricitinib), a JAK inhibitor used in the treatment of moderate-to-severe atopic dermatitis.